The FDA has released guidelines concerning journal reprints distributed to physicians that cite the off-label use of drugs and devices. Although some welcome the guidelines as a way to help clear up the issues surrounding the practice, others say they may cause confusion about what should or should not be considered promotional.
Source: AMANews (subscription required)
Dutch boast world’s first printed bike bridge
6 hours ago